Selinexor, Karyopharm Therapeutics' treatment for patients with multiple myeloma who have undergone at least three previous lines of therapy, was granted fast-track designation by the FDA. Top-line data from a study evaluating the drug is expected to be released by the end of the month.
FDA grants fast-track designation to Karyopharm's multiple myeloma drug
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.